JUL 26, 2016 5:40 AM PDT

Certain Colon Cancer Can be 'Starved' to Death

WRITTEN BY: Xuan Pham

Colon cancer is the third most common non-skin cancer type in the U.S. Now researchers say they have gained a huge advantage in discovering the key compound that sustains a large portion of these cancers. By blocking the compound, researchers showed significant tumor reduction. The findings are so promising that clinical trials for colorectal cancer patients will be starting this August at the University Hospitals Seidman Cancer Center.
 


Approximately over 1 million Americans are diagnosed with colorectal cancer, also known as colon cancer. Of these cases, about a third are due to mutations in a gene known as PIK3CA, which is involved in critical cell signaling processes such as cell growth and division, migration, and survival. Mutations in this gene are also responsible for a host of other cancer types, including lung cancer, breast and ovarian cancer, and head and neck cancer.

In studying colon cancer cells with PIK3CA mutations, the team at Case Western Reserve noted a very specific pattern of metabolism. In particular, they found that cells with PIK3CA mutations broke down the amino acid glutamine at a significantly faster pace than cells without the mutation. The increased need for glutamine stemmed from cancer cells’ overactive enzyme activities. Thus, glutamine is necessary in the colon cancer cells’ survival.

“We discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs," said Zhenghe John Wang, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University, and senior author of the study.
 

Image credit: Pixabay.com

Indeed, when the team starved mutant cells of glutamine, they observed more cell death. Even more promising, when they reduced glutamine levels in mice with colon cancer, they saw slower and smaller tumor growths. The same treatment in cancer cells without the PIK3CA mutation were not effective, indicating a specific link between PIK3CA and glutamine.

Glutamine is a non-essential (or conditional) amino acid that can be made by the body under the appropriate conditions. Its levels can be easily modulated with glutamine blockers, making treatment relatively straightforward. Furthermore, because PIK3CA is a well-known player in many other types of cancer makes the results are broadly appealing. As such, Phase I/II clinical trials stemming from this study are already planned for this later this summer.

"This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center," according to Neal Meropol, chief of the division of hematology and oncology, and lead investigator for the trial.

Additional source: Case Western Reserve University materials via EurekAlert!

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 22, 2021
Cancer
Evaluating adverse effects of induction therapy for neuroblastoma
JUN 22, 2021
Evaluating adverse effects of induction therapy for neuroblastoma
A study published in the Journal of Clinical Oncology reports an evaluation of the chemotherapy treatment given to child ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
AUG 23, 2021
Cancer
A Safe and Effective Combination Therapy for Advanced Cancer
AUG 23, 2021
A Safe and Effective Combination Therapy for Advanced Cancer
Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have m ...
AUG 24, 2021
Technology
CRISPR Helps Identify New Therapeutic Target for Leukemia
AUG 24, 2021
CRISPR Helps Identify New Therapeutic Target for Leukemia
Researchers may have found a new druggable target in patients with acute myeloid leukemia (AML), thanks to a CRISPR scre ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
OCT 21, 2021
Cancer
Exercise: A Secret Weapon to Combat Prostate Cancer?
OCT 21, 2021
Exercise: A Secret Weapon to Combat Prostate Cancer?
Exercise oncology is an evolving science that considers the addition of physical activity regimens to the treatment ...
Loading Comments...